Successful Treatment of Aggressive Post Transplant Lymphoproliferative Disorder using Rituximab

Abstract

A 52 year-old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosupression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproliferative disorder.

Key Words:

• post transplant lymphoproliferativse disorder
• treatment
• Rituximab
• CD20
• EBV
• immunosuppression
• organ